NGM Biopharmaceuticals Inc NGM:NASDAQ

Last Price$16.10NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/17/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$11.97 (4)
Ask (Size)$16.25 (7)
Day Low / HighN/A - N/A
Volume26.2 K
 

View Biotechnology IndustryPeer Comparison as of 09/17/2019

 

NGM Biopharmaceuticals Inc ( NASDAQ )

Price: $16.10
Change: +0.37 (2.35%)
Volume: 26.2 K
4:00PM ET 9/17/2019
 
 

Spectrum Pharmaceuticals Inc ( NASDAQ )

Price: $9.45
Change: +0.005 (0.05%)
Volume: 1.0 M
3:59PM ET 9/17/2019
 
 

Epizyme Inc ( NASDAQ )

Price: $11.74
Change: +0.01 (0.09%)
Volume: 959.8 K
3:59PM ET 9/17/2019
 
 

Intrexon Corp ( NASDAQ )

Price: $6.37
Change: +0.005 (0.08%)
Volume: 1.0 M
4:00PM ET 9/17/2019
 
 

Cara Therapeutics Inc ( NASDAQ )

Price: $23.73
Change: +0.02 (0.08%)
Volume: 10.00
3:59PM ET 9/17/2019
 

Read more news Recent News

Analyst Actions: Stifel Nicolaus Starts NGM Biopharmaceuticals at Buy, With $26 Price Target
10:50AM ET 6/25/2019 MT Newswires

NGM Biopharmaceuticals' (NGM) average rating among analysts is a buy, with an average price target of $26. Price: 14.45, Change: +0.60, Percent Change:...

NGM to Present Data From Study of Drug for Obese, Insulin Resistant Patients
9:59AM ET 6/05/2019 MT Newswires

NGM Biopharmaceuticals (NGM) on Wednesday said it will present new data from a phase 1b study of NGM313 at the 79th Scientific Sessions of the American...

NGM Biopharmaceuticals Q1 Loss Widens from Year Ago Amid Higher Revenue
5:14PM ET 5/16/2019 MT Newswires

NGM Biopharmaceuticals' (NGM) net loss widened to $1.21 per share in Q1 from $0.64 per share a year earlier, even as revenue rose to $25.55 million from...

Analyst Actions: Citigroup Starts NGM Biopharmaceuticals at Buy, With $29 Price Target
10:42AM ET 4/29/2019 MT Newswires

NGM Biopharmaceuticals' (NGM) average rating among analysts is a buy, with an average price target of $25. Price: 15.90, Change: +0.21, Percent Change:...

View all Commentary and Analysis

Daily Insider Ratings Round Up 8/9/19
5:49PM ET 8/14/2019 Seeking Alpha

Daily Insider Ratings Round Up 7/17/19
6:38AM ET 7/19/2019 Seeking Alpha

Mirum Pharmaceuticals IPO: At Phase 3 Of Development
1:25PM ET 7/17/2019 Seeking Alpha

NGM Biopharmaceuticals And NGM282 In Primary Biliary Cirrhosis: A Rapid Clinical Benefit
11:52PM ET 7/16/2019 Seeking Alpha

Company Profile

Business DescriptionNGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA. View company web site for more details
Address333 Oyster Point Boulevard
South San Francisco, California 94080-7014
Phone+1.650.243.5555
Number of EmployeesN/A
Recent SEC Filing08/12/20198-K
Executive Chairman & SecretaryWilliam J. Rieflin
Chief Executive & Financial Officer, DirectorDavid J. Woodhouse
President & Chief Operating OfficerAetna Wun Trombley
Director & Chief Scientific OfficerJin-Long Chen

Company Highlights

Price Open$15.81
Previous Close$16.10
52 Week Range$12.00 - 19.27
Market Capitalization$1.1 B
Shares Outstanding66.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/11/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.25
Beta vs. S&P 500N/A
Revenue$108.7 M
Net Profit Margin-31.31%
Return on Equity-12.21%

Analyst Ratings as of 08/25/2019

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset